Clinical Trial Update: A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia [Phase 3]

View source ↗

Summary

Phase III randomized, double-blind, multicenter trial comparing the combination of fimasartan and rosuvastatin to each component alone in patients with essentia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Essential Hypertension

Drugs mentioned

• Fimasartan (fimasartan)
• Rosuvastatin (rosuvastatin)

Snippet

Sponsor: Boryung Pharmaceutical Co., Ltd | Conditions: Essential Hypertension, Dyslipidemia | Phase 3 | Status: COMPLETED